Alnylam Pharmaceuticals Inc
XMUN:DUL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alnylam Pharmaceuticals Inc
XMUN:DUL
|
US |
|
M
|
Mckesson Corp
XMUN:MCK
|
US |
|
D
|
Daimler Truck Holding AG
XMUN:DTG
|
DE |
|
Akari Therapeutics PLC
F:CLA
|
US |
|
Compagnie Generale des Etablissements Michelin SCA
F:MCHA
|
FR |
|
C
|
Constellation Brands Inc
XMUN:CB1A
|
US |
|
Fugro NV
OTC:FUGRF
|
NL |
Wall St Price Targets
DUL Price Targets Summary
Alnylam Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for DUL is 391.59 EUR with a low forecast of 205.44 EUR and a high forecast of 512.23 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is DUL's stock price target?
Price Target
391.59
EUR
According to Wall Street analysts, the average 1-year price target for DUL is 391.59 EUR with a low forecast of 205.44 EUR and a high forecast of 512.23 EUR.
What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
34%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 3 years is 34%.
What is the Gross Profit forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
31%
The compound annual growth rate for Gross Profit over the next 3 years is 31%.
What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
72%
The compound annual growth rate for Operating Income over the next 3 years is 72%.
What is the Pre-Tax Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
93%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 93%.
What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
87%
The compound annual growth rate for Net Income over the next 3 years is 87%.
